VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zebra 365 who wrote (5354)	2/9/1998 12:26:00 PM
From: Tunica Albuginea	Read Replies (1) of 23519

Zebra,I pulled out my crystal ball this morning and thoughtI'd bounce off you what I see. I think there is still short selling going on in Vivus. I believe short sellers are interested in keeping the price down so as not to get near 20 by the time UK and FDA approval comes around. That's because those approvals in early spring are likely to come before any FDA approval of Viagra is late spring (if it is approved that is). Well it is extremely likely that those 2 approvals will take Vivus up 6 points at least if not significantly more being that now Vivus will have a clear unobstructed pathway into selling giants amount of product with great earnings increase. If the stock starts the spring season in the low 20s the shorts will become Chopsuey and a distant memory. So we can't let that happen can we? So the plan is to continue to sell short. There is only one small problem that I can see with that scenario and I'll run the math by you since you seem well versed in it (from previous scrubs with your service in IRS, gg those guys sure know their math don't they? ): a successful short selling strategy presupposes 2 things: A continuously available supply of stock to short and a drying up of Vivus new buyers. The problem that I see is that these 2 strategic pillars for shorting in Vivus case are not assured at all. The stock is already highly shorted and whatever is left is likely to dry up in the next 1 month of shorting. Second, there will be continuously new buyers of Vivus as the product continues to succeed even more in the marketplace according to the data I am getting from all my colleagues (as I promised to post later). So my question to you is this: do you see a shorts-bonfire looming in the not too distant horizon as I do? Off to work now to write more MUSE prescriptions, GG.I'll check out your reply tonight. Have a good prescription day! TA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next